Analysis of pregnancy outcomes in patients with polycystic ovary syndrome after clinical intervention with human assisted reproductive technology

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074494

Enrollment

Unknown

Registered

2023-08-08

Start date

2021-01-29

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Treatment group:Pharmacological intervention

Control group:N/A

Eligibility

Sex/Gender

Female

Age

20 Years to 46 Years

Inclusion criteria

Inclusion criteria: PCOS can be defined if at least 2 of the following 3 criteria are present: ? Watery ovulation or chronic anovulation (OA); ? Clinical manifestations of hyperandrogenemia or hyperandrogenism (HA); ? Ultrasonic monitoring of polycystic ovarian changes (PCO)

Exclusion criteria

Exclusion criteria: Conjunctivitis of AIH, uterine malformations, bilateral fallopian tube obstruction, chromosomal abnormalities, rheumatic immune system diseases, untreated endometrial diseases, patients with drug allergy, severe psychiatric system diseases, pituitary tumors, congenital diseases, abnormal blood glucose, blood pressure, thyroid function, prolactin, etc

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate;Abortion rate;Oocyte tetrieval rate;High quality embryo number;	—

Countries

China

Contacts

Public ContactLi Fei

The First People's Hospital of Shangqiu

xylaoli15@163.com+86 135 2631 1080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026